205 related articles for article (PubMed ID: 36647058)
1. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response.
Chen ZH; Zheng WH; Wu CF; Kou J; Yang XL; Lin L; Lv JW; Sun Y; Zhou GQ
BMC Med; 2023 Jan; 21(1):18. PubMed ID: 36647058
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
Lu Y; Li Q; Xu L; Zheng Y; Wang Y; Liu Y; Zhang R; Liao L; Dong J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16501-16510. PubMed ID: 37715029
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
[TBL] [Abstract][Full Text] [Related]
5. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
7. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.
Tang X; Zhou W; Huang D; Chen L; Zhang G
Front Immunol; 2021; 12():688682. PubMed ID: 34804001
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
11. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
12. Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma.
Yang X; Ren H; Li Z; Peng X; Fu J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111094. PubMed ID: 37871379
[TBL] [Abstract][Full Text] [Related]
13. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
Peng Z; Wang Y; Fang Y; Wang Y; Yuan X; Shuai M; Xie S; Fan R; Zhang H; Xie Z; Jiang W
Front Immunol; 2022; 13():899932. PubMed ID: 35686123
[TBL] [Abstract][Full Text] [Related]
14. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
15. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of hypothyroidism in patients undergoing intensity-modulated radiation therapy for nasopharyngeal carcinoma.
Weng JJ; Wei JZ; Li M; Ning LP; Liu F; Wei YZ; Xiong WM; Zhang BJ; Lu JL; Jiang H; Lu QT; Qu SH
Head Neck; 2022 May; 44(5):1114-1123. PubMed ID: 35170140
[TBL] [Abstract][Full Text] [Related]
17. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis.
Zhi-Qiang W; Qi M; Ji-Bin L; Rui Y; You-Ping L; Rui S; Guang-Yuan H; Ming-Yuan C; Yi-Jun H
BMC Cancer; 2019 Nov; 19(1):1122. PubMed ID: 31744469
[TBL] [Abstract][Full Text] [Related]
18. Thyroid V
Zhou L; Chen J; Shen W; Chen ZL; Huang S; Tao CJ; Chen M; Yu ZH; Chen YY
Radiat Oncol; 2020 Mar; 15(1):68. PubMed ID: 32293496
[TBL] [Abstract][Full Text] [Related]
19. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
